Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease
References (36)
- et al.
Clusterin: the intriguing guises of a widely expressed glycoprotein
Trends Biochem Sci.
(1992) - et al.
Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning
Brain Res.
(1991) - et al.
Immunohistochemical quantification of of the synapse related protein synaptophysin in Alzheimer's disease
Neurosci. Lett.
(1989) - et al.
Dynamics of gene expression for hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in the rats
Neuron
(1990) - et al.
Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration
Trends Neurosci.
(1992) - et al.
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease
Brain Res.
(1991) - et al.
Apolipoprotein E-and GFAP-RNA in hippocampus during reactive synaptogenesis and terminal proliferation
Mol. Brain Res.
(1991) - et al.
Role of hippocampal cholesterol synthesis and uptake during reactive synaptogenesis in adult rats
Neuroscience
(1993) - et al.
Apolipoprotein E and Alzheimer's disease
Lancet
(1993) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
Trends Neurosci.
(1994)
Apolipoprotein E: binding to soluble Alzheimer's β-amyloid
Biochem. Biophys. Res. Commun.
Purification and characterization of brain clusterin
Biochem. Biophys. Res. Commun.
Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection
Distribution of herpes virus type I DNA in selected areas of normal and Alzheimer's disease brains
Neurodegeneration
Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease
Neuroreport
A role for apolipoprotein E, apolipoprotein A-1, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of rat sciatic nerve
J. Clin. Invest.
SP-40,40 is a constituent of Alzheimer's amyloid
Acta Neuropathol.
Gene dose of apolipoprotein E type 4 and risk of Alzheimer's disease in late onset families
Science
Cited by (197)
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
2022, Neurobiology of AgingCitation Excerpt :Nevertheless, these findings suggest that PCSK9 inhibition represents a therapeutic approach for AD therapy. While some studies have shown that apoE levels are upregulated in human AD brains and CSF when compared to controls (Akram et al 2012, Lee et al 2020, Sihlbom et al 2008, Toledo et al 2014), others have reported that apoE levels are not changed (Martinez-Morillo et al 2014, Pirttila et al 1996, Schmidt et al 2014) or decreased (Bertrand et al 1995, Cruchaga et al 2012, Talwar et al 2016). Although studies on apoE mRNA or protein levels in human AD brains have yielded contradictory results, recent studies with single-cell RNA-sequencing, and transcriptomic analyses of isolated microglia have revealed that Apoe is one of the most upregulated genes in a subset of microglia with neurodegenerative phenotype in amyloid mouse models (Keren-Shaul et al 2017, Krasemann et al 2017).
APOE signaling in neurodegenerative diseases: an integrative approach targeting APOE coding and noncoding variants for disease intervention
2021, Current Opinion in NeurobiologyAPOE ε4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease
2020, Neurobiology of Aging